ASCO 2019 Ramucirumab plus erlotinib improves progression-free survival in EGFR-positive lung cancer Read more
ASCO 2019 FOLFOXIRI + bevacizumab shows progression-free survival benefit in mCRC patients with ≥3 bas... Read more
ASCO 2019 Pembrolizumab increases historic survival rate for certain people with advanced NSC lung cance... Read more